You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -117.0% | -143.0% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -9.0 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 8.5 | 7.4 |
| Price / Book value | 1.5 |
| Latest | Forecast | |
|---|---|---|
| Revenue | -60.9% | -9.5% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | -7.6% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | 21.62 | -12.89 | $-0.23 | -7.2 | 0.0 | n/a | n/a | 0.0% |
| 2020-12-31 | 26.00 | -11.82 | $-0.17 | -42.4 | 0.0 | n/a | n/a | 0.0% |
| 2021-12-31 | 33.89 | -19.08 | $-0.21 | -48.6 | 0.0 | n/a | n/a | 0.0% |
| 2022-12-31 | 44.26 | -23.57 | $-0.55 | -9.6 | 0.0 | n/a | n/a | 0.0% |
| 2023-12-31 | 41.29 | -37.92 | $-0.37 | -12.1 | 0.0 | n/a | n/a | 0.0% |
| MaxCyte appoints new chief commercial officer Sharecast News | 10 Oct |
|---|---|
| MaxCyte enters licence agreement with Kamau Therapeutics Sharecast News | 16 Sep |
| MaxCyte reports solid second-quarter performance Sharecast News | 07 Aug |
| Holding(s) in Company | 19-Nov-24 09:50 |
|---|---|
| Filing of 10Q form | 07-Nov-24 07:01 |
| Third Quarter 2024 Financial Results | 07-Nov-24 07:02 |
| Exercise of options and PDMR dealing | 06-Nov-24 13:44 |
| Total Voting Rights | 04-Nov-24 13:23 |